The US FDA will be releasing in the next six months a guidance on the clinical evaluation of targeted therapies for rare disease subsets as part of a broader "medical innovation development plan"designed to facilitate the development of breakthrough new treatments, agency Commissioner Scott Gottlieb announced.
Testifying June 20 before the Senate Appropriations Subcommittee on Agriculture, Rural Development, Food and Drug Administration and Related Agencies, Gottlieb...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?